Dr. Ali Motevalizadeh Ardekani

Dr. Ali Motevalizadeh Ardekani

Member
The Academy of Sciences, Islamic republic of Iran


Highest Degree
Ph.D. in Endocrinology from Shahid Beheshti University, Iran

Share this Profile

Biography

Dr. Ali M. Ardekani is currently working as Associate Professor at National Institute of Genetic Engineering and Biotechnology Shahrake Pajoohesh, Tehran-Iran, and Director at Middle-Eastern Association for Cancer Research, Canada, and Health Biotechnology Convention Pasteur Institute of Iran. He obtained his Ph.D. in Endocrinology from Shahid Beheshti University, Iran. Dr. Ali M. Ardekani received honors includes Recipient of a 42,000.00 Grant from the International Center for Genetic Engineering and Biotechnology (ICGEB) from the country of Iran, Cancer Research Award, National Cancer Institute, USA, NIH Postdoctoral Training Grant, Northwestern University, IL, and AACR-AFLAC Scholar in Cancer Research Award. He is member of Iran National Cancer steering Committee and a founding member of the Iranian society for Health Genomics and Biotechnology, Eastern Association for Cancer Research (MEACR), National Cancer Research and Education Committee, Iran cancer Society, One of the Founders and member of the board of Directors in Health Biotechnology Society (Iran). He is Founder and first Editor-in-Chief of Avicenna Journal of Medical Biotechnology, and member of editorial board in journals. He has published 8 books, 1 book chapter, 1 news paper article, 3 abstracts, and 88 articles in journals contributed as author/co-author. He also worked on 6 research projects as Principal Investigator and Co-investigators. He successfully supervised 2 PhD degrees, and 17 Masters students.

Area of Interest:

Biomedical Sciences
100%
Marine Biology
62%
Endocrinology
90%
Gastroenterology
75%
Liver Diseases
55%

Selected Publications

  1. Ardekani, A.M. and M. Shirzad, 2019. Genetically Modified (GM) foods and the risk to human health and environment. Health Biotechnol. Biopharma J., 3: 61-73.
  2. Abbasian, M.H., B. Abbasi, N. Ansarinejad, A.M. Ardekani, E. Samizadeh, K.G. Moghaddam and M.R. Hashemi, 2018. Association of interleukin-1 gene polymorphism with risk of gastric and colorectal cancers in an Iranian population. Iran. J. Immunol., 15: 321-328.
    Direct Link  |  
  3. Sehati, N., P. Kokhaei, A.M. Ardekani, R. Tootoonchian and F. Pak, 2017. Evaluation of serum interleukin-21 and HLA-C1 polymorphism in pediatrician hematopoietic stem cell transplantation for early diagnosis of acute graft-versus-host disease. Iran. Biomed. J., 21: 392-399.
    CrossRef  |  PubMed  |  Direct Link  |  
  4. Ardekani, A.M., M. Shirani, A. Hashemi, Z. Basiri and Y. Rahmati et al., 2017. Methylation status of NANOG1, RASSF1A, SFN, CASP8, WIF1, CTSL2 genes in Iranian breast cancer patients. Iran. South Med. J., 19: 940-950.
    CrossRef  |  Direct Link  |  
  5. Tootoonchian, R., F. Pak, A.M. Ardekani, N. Sehati, M. Abedi-Valugerdi and P. Kokhaei, 2016. Evaluation of interleukin 12 and CD56 + lymphocyte cells in pediatric hematopoietic stem cell transplantation for early diagnosis of acute graft versus host disease. Transplant Immunol., 39: 25-29.
    CrossRef  |  Direct Link  |  
  6. Moosavi, A. and A.M. Ardekani, 2016. Role of epigenetics in biology and human diseases. Iran. Biomed. J., 20: 246-258.
    CrossRef  |  PubMed  |  Direct Link  |  
  7. Fadaeipour, S., Z Babaei, H. Parsian, A.M. Ardekani and N. Nikbakhsh, 2016. Comparison of the serum total bile acids and cholesterol levels in breast cancer patients with control group. J. Babol Univ. Med. Sci., 18: 48-53.
    Direct Link  |  
  8. Ardekani, A.M.Z., 2016. The human genome project: Ethical and legal challenges in human societies. Iran. J. Bioethics, 19: 101-124.
    Direct Link  |  
  9. Ajami, M., M. Alimoradi and A.M. Ardekani, 2016. Biotechnology: Two decades of experimentation with genetically modified foods. Applied Food Biotechnol., 3: 228-235.
    Direct Link  |  
  10. Naemi, S., A.M. Ardekani, A. Ghaderi and N. Erfani, 2015. Investigation of E-cadherin expression in peripheral blood of patients with breast cancer in a population from southern Iran. Iran. South Med. J., 18: 117-124.
  11. Gharibiyan, A., S.A. Hashemi, M. Hadi, H. Abdolghafoorian and A.M. Ardekani, 2015. Serum/plasma DNA methylation pattern and early detection of breast cancer. Clin. Cancer Invest. J., 4: 120-128.
    CrossRef  |  Direct Link  |  
  12. Boroumand, M. and A.M. Ardekani, 2015. Alcohol and women's health. J. Social Issues Humanit., 3: 2345-2633.
  13. Naeimi, S., N. Erfani, A.M. Ardekani and A. Ghaderi, 2014. Variation of IL-17A and IL-17F genes in patients with breast cancer in a population from southern Iran. Adv. Environ. Biol., 8: 892-897.
  14. Maghsoudi, N., R. Ghasemi, Z. Ghaempanah, A.M. Ardekani and E. Nooshinfar, 2014. Effect of chronic restraint stress on HPA axis activity and expression of BDNF and Trkb in the hippocampus of pregnant rats: Possible contribution in depression during pregnancy and postpartum period. Basic Clin. Neurosci. J., 5: 131-137.
    Direct Link  |  
  15. Ardekani, A.M., 2014. Genetically modified foods and health concerns. Iran. J. Biotechnol., 12: 1-2.
    CrossRef  |  Direct Link  |  
  16. Amanpour, T., A. Bazgir, A.M. Ardekani and R. Ghahremanzadeh, 2014. Pseudo five-component synthesis of 5-phenyldihydrospiro [diindenopyridine-indenoquinoxaline] dione derivatives via a one-pot condensation reaction. Monatshefte fur Chemie-Chem. Monthly, 145: 627-632.
    CrossRef  |  Direct Link  |  
  17. Alimardani, A., A.M. Ardekani and L.R. Astany, 2014. A bio-social review to mitigate the punishment of unwanted acts. Int. J. Criminol. Sociol., 3: 348-359.
    Direct Link  |  
  18. Saliminejad, K., T. Memariani, A.M. Ardekani, K. Kamali, H.E.Z. Pahlevanzadeh and H.R.K. Khorshid, 2013. Association study of the TNF-α-1031T/C and VEGF+450G/C polymorphisms with susceptibility to endometriosis. Gynecol. Endocrinol., 29: 974-977.
    CrossRef  |  Direct Link  |  
  19. Fattahi, S., A.M. Ardekani, E. Zabihi, Z. Abedian, A. Mostafazadeh, R. Pourbagher and H. Akhavan-Niaki, 2013. Antioxidant and apoptotic effects of an aqueous extract of Urtica dioica on the MCF-7 human breast cancer cell line. Asian Pac. J. Cancer Prev., 14: 5317-5323.
    PubMed  |  Direct Link  |  
  20. Pandamooz, S., A. Hadipour, H. Akhavan-Niaki, M. Pourghasem and Z. Abedian et al., 2012. Short exposure to collagenase and coculture with mouse embryonic pancreas improve human dermal fibroblast culture. Biotechnol. Applied Biochem., 59: 254-261.
    CrossRef  |  Direct Link  |  
  21. Khanaki, K., M. Nouri, M. Ardekani, A. Ghassemzadeh and V. Shahnazi et al., 2012. Evaluation of the relationship between endometriosis and omega-3 and omega-6 polyunsaturated fatty acids. Iranian Biomed. J., 16: 38-43.
    Direct Link  |  
  22. Khanaki, K., A.M. Ardekani, A. Ghassemzadeh, V. Shahnazi and M.R. Sadeghi et al., 2012. Effect of polyunsaturated fatty acids on secretory phospholipase A2 type IIa in ectopic endometrial cells. Iran. J. Reprod. Med., 10: 321-328.
    Direct Link  |  
  23. Ghorbian, S. and A.M. Ardekani, 2012. Non-invasive detection of esophageal cancer using genetic changes in circulating cell-free DNA. Avicenna J. Med. Biotechnol., 4: 3-13.
    Direct Link  |  
  24. Fard, S.S., M.J. Tehrani and A.M. Ardekani, 2012. Prostaglandin E2 induces growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6). Prostaglandins Leukotrienes Essential Fatty Acids, 87: 17-24.
    CrossRef  |  Direct Link  |  
  25. Ardekani, A.M.Z., M. Hashemi, M.S. Kish, A.A. Bagheri, S.B. Shekoohi and M. Mosadegh, 2012. Cancer drug treatment in Persian traditional medicine sources. Iran. Islamic Tradit. Med. J., 3: 3-18.
  26. Pandamooz, S., H. Akhavan-Niaki, N. Mousavi Kani, Z. Abedian, A.M. Ardekani, A. Hadipour and A. Mostafazadeh, 2011. Improved protocol for isolating dermal fibroblasts. Cell J., 13: 22-22.
    Direct Link  |  
  27. Maghari, B.M. and A.M. Ardekani, 2011. Genetically modified foods and social concerns. Avicenna J. Med. Biotechnol., 3: 109-117.
  28. Ardekani, A.M., S.S. Fard, M.J. Tehrani and R. Ghahremanzade, 2011. Fenretinide, 1α,25(OH)2D3 and Bryostatin-1 induce cell cycle arrest, apoptosis and differentiation in human acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6). Avicenna J. Med. Biotechnol., 3: 177-193.
    Direct Link  |  
  29. Ardekani, A.M., N. Maghsudi, A. Meyfour, R. Ghasemi, N. Lakpour, E. Nooshinfar and Z. Ghaempanah, 2011. Stress-induced proteomic changes in the hippocampus of pregnant wistar rats. Avicenna J. Med. Biotechnol., 3: 157-166.
    Direct Link  |  
  30. Ardekani, A.M., 2011. Ethical challenges in applications of reproductive biotechnologies. Cell J., 13: 10-10.
    Direct Link  |  
  31. Ahmadi, M. and A.M. Ardekani, 2011. Genetic privacy and genetic information of patients. Med. Genet. J., 5: 89-113.
  32. Abdollahpour, M., R. Tahamtan, F. Samani, Z. Deldar and M. Dehghan et al., 2011. Frequency of familial history in population with breast cancer referred to babol educational hospitals during 2007-2010. Cell J., 13: 26-27.
    Direct Link  |  
  33. Soudabeh, S., A.M. Ardakani, H. Mahshid, A.M. Mehdi and S.G. Haleh et al., 2010. Comparing seminal plasma biomarkers between normospermic and azoospermic men. J. Reprod. Infertil., 11: 39-46.
    Direct Link  |  
  34. Jabbari, S., M.R. Sadeghi, M.M. Akhondi, E.H. Azadeh and N. Amirjanati et al., 2010. Tyrosine phosphorylation pattern in sperm proteins isolated from normospermic and teratospermic men. J. Reprod. Infertil., 10: 185-191.
    Direct Link  |  
  35. Fard, S.S., M. Jeddi-Tehrani, M.M. Akhondi, M. Hashemi and A.M. Ardekani, 2010. Flow cytometric analysis of 4-HPR-induced apoptosis and cell cycle arrest in acute myelocytic leukemia cell line (NB-4). Avicenna J. Med. Biotech., 2: 53-61.
    Direct Link  |  
  36. Ardekani, A.M. and M. Moslemi, 2010. The role of miRNAs and human diseases. Avicenna J. Med. Biotechnol., 2: 161-179.
    Direct Link  |  
  37. Sudabeh, J. and A.M. Ardekani, 2009. Genetics and ethical issues. Q. J. Med. Ethics, 2: 121-131.
  38. Shabnam, B. and A.M. Ardekani, 2009. Gene therapy and medical ethics. Q. J. Med. Ethics, 2: 189-198.
  39. Naeini, M.M. and A.M. Ardekani, 2009. Noncoding RNAs and cancer. Avicenna J. Med. Biotech., 1: 55-70.
    Direct Link  |  
  40. Ardekani, A.M., 2009. Genetic technologies and ethics. J. Med. Ethics Hist. Med., 2: 11-11.
    Direct Link  |  
  41. Ardekani, A.M., 2009. Genetic behavior and culture. Med. Ethics J., 7: 65-84.
  42. Ardekani, A.M. and S. Jabbari, 2009. Nutrigenomics and cancer. Avicenna J. Med. Biotech., 1: 9-17.
    Direct Link  |  
  43. Dezfulian, A., A.M.Z. Ardekani, M.M. Aslani, H. Dabiri and M.R. Zali, 2008. Influence of the probiotic escherichia coli strain Nissle 1917 on the growth of different pathogenic bacteria isolated from patients with diarrhea. Gastroenterol. Hepatol. Bed Bench, 3: 113-117.
  44. Ardekani, A.M., M.M. Akhondi and M.R. Sadeghi, 2008. Application of genomics and proteomics technologies to early detection of cancer. Arch. Iran Med., 111: 427-434.
    PubMed  |  Direct Link  |  
  45. Ardekani, A.M., M.M. Akhondi and M.R. Sadeghi, 2008. Application of genomic and proteomic technologies to early detection of cancer. Arch. Iran. Med., 11: 427-434.
    PubMed  |  
  46. Ardekani, A.M., A. Ferial and N. Lakpour, 2007. Application of genomics and proteomics technologies to early diagnosis of reproductive organ cancers. J. Reprod. Infertil., 8: 259-278.
    Direct Link  |  
  47. Petricoin, E.F., V. Rajapaske, E.H. Herman, A.M. Ardekani and S. Ross et al., 2004. Toxicoproteomics: Serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. Toxicol. Pathol., 32: 122-130.
    PubMed  |  
  48. Liotta, L.A., E.F. Petricoin, A.M. Ardekani, B.A. Hitt and P.J. Levine, et al., 2003. General keynote: Proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecologic Oncol., 88: S25-S28.
    CrossRef  |  
  49. Ardekani, A.M., E.F. Petricoin and J. Hackett, 2003. Molecular diagnostics: An FDA perspective. Expert Rev. Mol. Diag., 3: 129-140.
    CrossRef  |  
  50. Petricoin, E.F., D.K. Ornstein, C.P. Paweletz, A. Ardekani and P.S. Hackett et al., 2002. Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst., 94: 1576-1578.
    PubMed  |  
  51. Petricoin, E.F., A.M. Ardekani, B.A. Hitt, P.J. Levine and V.A. Fusaro et al., 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359: 572-577.
    CrossRef  |  
  52. Michener, C.M., A.M. Ardekani, E.F. Petricoin, L.A. Liotta and E.C. Kohn, 2002. Genomics and proteomics: Application of novel technology to early detection and prevention of cancer. Cancer Detection Prev., 26: 249-255.
    Direct Link  |  
  53. Leak, L.V., E.F. Petricoin, M. Jones, C.P. Paweletz and A.M. Aredekani et al., 2002. Proteomic technologies to study diseases of the lymphatic vascular system. Ann. N.Y. Acad. Sci., 979: 211-228.
    PubMed  |  
  54. Ardekani, A.M., L.A. Liotta and E.F. Petricoin, 2002. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev. Mol. Diagn., 2: 312-320.
    PubMed  |  
  55. Ardekani, A.M., E.H. Herman, F.D. Sistare, L.A. Liotta and E.F. Petricoin, 2001. Molecular profiling of cancer and drug-induced toxicity using new proteomics technologies. Curr. Ther. Res., 62: 803-819.
    CrossRef  |  
  56. Ardekani, A.M., J.S. Greenberger and N. Jahroudi, 1998. Two repressor elements inhibit expression of the von willebrand factor gene promoter in vitro. Thromb. Homeost., 80: 488-494.
    PubMed  |  
  57. Ardekani, A.M., J.C. Romanelli and K.E. Mayo, 1998. Structure of the rat inhibin and activin βA-subunit gene and regulation in an ovarian granulosa cell line. Endocrinology, 139: 3271-3279.
    PubMed  |  
  58. Mayo, K.E., A. Mukherjee, A. Ardekani and I.W. Shu, 1997. Regulation of inhibin and activin subunit gene expression in ovarian granulosa cells. Biol. Reprod., 56: M20-M20.
  59. Jahroudi, N., A.M. Ardekani and J.S. Greenberger, 1996. Ionizing irradiation increases transcription of the von willebrand factor gene in endothelial cells. Blood, 88: 3801-3814.
    PubMed  |  
  60. Jahroudi, N., A.M. Ardekani and J.S. Greenberger, 1996. An NF1-like protein functions as a repressor of the von Willedbrand factor promoter. J. Biol. Chem., 271: 21413-21421.
    PubMed  |  
  61. Jahroudi, N., A. Ardekani and J.S. Greenberger, 1996. Two repressor elements regulate endothelial-specific activation of the VWF promoter. Blood, 88: 2028-2028.
  62. Bahrmand, A.R., H. Nekoui and A.M. Ardekani, 1996. New solid culture media for growing borrelia persica and borrelia microti. Rev. Cubana Med. Trop., 48: 40-44.
    PubMed  |  
  63. Jahroudi, N., A. Ardekani and J.S. Greenberger, 1995. The von-willebrand-factor gene-transcription is increased in response to ionizing irradiation. Exp. Hematol., 23: 779-779.
  64. Jahroudi, N., A. Ardekani and J.S. Greenberger, 1995. Ionizing irradiation increases transcription of the von willebrand factor gene in endothelial cells. Blood, 86: 3486-3486.
  65. Jahroudi, N., A. Ardekani and J.S. Greenberger, 1995. An NF-1-like protein functions as a repressor of the vWf promoter. Blood, 86: 307-307.
  66. Van Dyke, K., P. Allender, L. Wu, J. Gutierrez, J. Garcia, A.M. Ardekani and W. Karo, 1990. Luminol-or lucigenin-coated micropolystyrene beads, a single reagent to study opsonin-independent phagocytosis by cellular chemiluminescence: Reaction with human neutrophils, monocytes and differentiated HL-60 cells. Microchem. J., 41: 196-209.
  67. Van Dyke, K., P. Allender, L. Wu, J. Gutierrez, J. Garcia, A.M. Ardekani and W. Karo, 1990. Luminol or lucigenin-coated polystyrene beads, a single reagent to study opsonin independent phagocytosis by cellular L-60 cells. Microchem. J., 41: 196-209.
  68. Ardekani, A.M., S.J. Walker, S.J. Donohue, R.E. Stitzel, J.M. Conners and K.E. Vrana, 1989. Adrenocorticotropin and corticosterone levels in pre-weaning spontaneously hypertensive rats. Life Sci., 44: 919-925.
    CrossRef  |  
  69. Ardekani, A.M., P. de Baetselier and K. Van Dyke, 1989. Chemiluminescent response in murine peritoneal macrophage hybridoma-cell line (2C11-12) primed with lipopolysaccharide (LPS) and Interferon-β. Microchem. J., 40: 139-151.
  70. Ardekani, A.M. and K. Van Dyke, 1989. Myeloperoxidase involvement in PMA induced chemiluminescence in retinoic-acid-differentiated HL-60 cells. Microchem. J., 39: 317-329.
    CrossRef  |  
  71. Peden, D., K. van Dyke, A. Ardekani, M. Mullett, D. Myerberg and C. van Dyke, 1987. Diminished chemiluminescent responses of polymorphonuclear leukocytes in preterm and very low birthweight neonates. J. Pediatrics, 111: 904-905.
  72. Peden, D., K. van Dyke, A. Ardekani, M. Mullett and W. Neal, 1986. Studies of neonatal polymorphonuclear leukocyte function using a novel microanalytic chemiluminescence technique. Microchem. J., 34: 222-229.
    Direct Link  |  
  73. Ardekani, A.M., D. English and K. van Dyke, 1986. The inhibition of luminol-dependent chemiluminescence of lipoxygenase, myeloperoxidase and human neutrophils by dipyridamole. Microchem. J., 33: 309-315.